Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Long term safety and long term disease control of oral ixazomib and short-course rituximab in untreated iNHL

View Full Paper
Ask AI
Bookmark
Share

Authors

SGSolomon A. GrafCUChaitra UjjaniTGTed Gooley

Discussion

Loading...

Member takes

Overview

Long-term treatment demonstrated safety and improved progression free survival in untreated iNHL, suggesting effective disease control.

Key Points

  • Assess long-term safety and efficacy of ixazomib and rituximab in untreated indolent B-cell non-Hodgkin lymphoma (iNHL).
  • Eligible untreated iNHL patients received oral ixazomib weekly and short-course rituximab.
  • Safety and efficacy were evaluated with a Kaplan Meier analysis over long-term follow-up.
  • Patients were monitored for adverse events (AEs) and progression free survival (PFS).
  • Median follow-up of 85 months showed a median PFS of 26 months for the entire cohort.
  • In 17 long-term patients, median PFS was 79 months, with a 5-year PFS estimate of 74%.
  • Among responders, the median duration of response was 73 months, and complete response 87 months.

Cite This Study

Graf et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db56https://doi.org/10.1182/blood-2025-5355
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Lenalidomide, rituximab (R <sup>2</sup> ), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma2024
  2. 2An open-label rollover study to assess the long-term safety of ixazomib2025
  3. 3Magrolimab Plus Rituximab in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Phase 1/2 Trial 3-Year Follow-up2024 · 11 citations
  4. 4Real-world efficacy and safety of ixazomib maintenance therapy in Chinese patients with newly diagnosed multiple myeloma: A multicenter retrospective study2025
  5. 5Treatment outcomes in patients with newly diagnosed multiple myeloma receiving ixazomib as initial therapy: A retrospective, observational, real-world historical database analysis from China2025